DPP-4is is a new class of anti-diabetes which can prevent the rapid degradation of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1(GLP-1) through inhibition of DPP-4 [1], thus enhancing insulin secretion [2]. This evidence concerns the gene GCG and diabetes mellitus.